Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Heavily Pretreated mCRPC (CYCLONE 1)
NCT04408924Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of abemaciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Started Jan 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04408924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408924.